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Abstract
Furin, a member the proprotein convertase (PC) family, processes inactive precursor proteins to functional proteins
within the Golgi/trans-Golgi network secretory pathway. Furin and other PC family members (furin/PCs) activate
proteins vital to proper physiological functioning, including growth factors and hormones, receptors, plasma pro-
teins, and matrix metalloproteases (MMPs). Additionally, the expression and activity of furin/PC are necessary for
processing substrates important for cell transformation and tumor progression, metastasis, and angiogenesis.
Furin processing of the remodeling protease membrane type-1 matrix metalloproteinase (MT1-MMP) enhances
cellular motility and invasiveness, contributing to aggression and metastatic potential cancer cells. Whereas over-
expression and activity of furin/PC exacerbate the cancer phenotype, inhibition of its activity decreases or nullifies
furin/PC–mediated effects, and thus, inhibition of furin may be a viable route to cancer therapy. Recently, we iden-
tified a small-molecule inhibitor of furin, named B3, by high-throughput screening with a Ki and IC50 of 12 μM. Here,
we show that this cell-permeable, small-molecule compound inhibits furin-mediated cleavage of proMT1-MMP,
resulting in decreased MMP-2 activation and cell motility in CHO cells expressing proMT1-MMP. Additionally, this
molecule inhibited proMT1-MMP processing, complete MMP-2 maturation, and invasiveness of human fibrosar-
coma cells (HT1080).
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Introduction
Furin, a ubiquitously expressed member the proprotein convertase
(PC) family, functions to process inactive precursor proteins to their
functional or mature forms at the specific recognition motif RXK/
RR↓ within the Golgi/trans-Golgi network secretory pathway [1,2].
Furin and other PC family members (furin/PC) process and activate
many proteins vital to the proper physiological functioning, including
growth factors and hormones, receptors, plasma proteins, and matrix
metalloproteases (MMPs) [2]. Although furin/PC processing is essen-
tial, its activity contributes to several pathologic conditions such as
Alzheimer’s disease, arthritis, atherosclerosis, and cancer [1,3,4].
Furin/PC expression and processing can increase the incidence and
severity of the cancer phenotype. Heightened furin expression and/or
furin/PC processing of substrates lead to cellular transformation and
promote tumor progression [5,6]. In fact, cancers found in the ovary
[7], breast [8], head and neck [9], and brain [10], as well as non–
small cell lung carcinomas [11], have increased furin expression com-
pared to their normal cell counterpart. This elevated expression often
results in an increase in tumor cell aggression and promotes forma-
tion of metastases, resulting in decreased patient survival. Furin/PC
processing of substrates also contributes to tumor progression, ag-
gressiveness, metastasis, and angiogenesis [12–15]. Furin/PC pro-
cessing of substrates such as platelet-derived growth factor A [16]
and B [17], insulin growth factor and its receptor [3], tumor necrosis
factor α [18], and transforming growth factor β [5,19] facilitates can-
cer progression and invasiveness [3,20]. Furin processing of MMPs,
such as intracellular remodeling proteases stromelysin-3 [21] and pro-
membrane type-1 matrix metalloproteinase (proMT1-MMP) [22],
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increases cell motility and invasion thus promoting metastases [12].
Specifically, proMT1-MMP processing by furin is required for MT1-
MMP activation [23], which results in the degradation of extra-
cellular matrix components such as fibronectin, fibrin, collagens,
and laminin-1 [24]. MT1-MMP also degrades adhesion molecules
such as CD44, integrins, and tissue transglutaminase [24]. Active
MT1-MMP activates other MMPs responsible for degrading extra-
cellular matrix components such as proMMP-2 (gelatinase) and
proMMP-13, further contributing to the metastatic potential of
the cell [24]. Thus, the expression and activity of furin/PC directly
enhances progression, aggression, and metastatic potential of tumor
cells [21].
Existing evidence indicates that furin inhibition can be a viable
route to cancer therapy [6,20]. For example, treatment of cultured
human fibrosarcoma cells with the furin inhibitor decanoyl-Arg-
Val-Lys-Arg-chloromethylketone (decRVKR-CMK) decreased
MT1-MMP maturation and invasive ability of these cells [25]. More-
over, transfection of the furin inhibitor, alpha 1-antitrypsin Portland
(α1-PDX), in MT1-MMP–expressing cells inhibited MMP-related
cell motility [23], cell growth, and invasiveness of glioma tumor cell
lines [10] and of colon adenocarcinoma cells [26] both in vitro and
in vivo. Although these furin inhibitors are effective in combating
cancer in vitro (decRVKR-CMK and α1-PDX) and in vivo (α1-
PDX) [6], these and other furin inhibitors [27–32] have not been
developed as pharmaceuticals due to issues with size, stability, and
toxicity [6,33,34]. Further, to combat furin/PC–mediated MT1-
MMP–related motility and invasiveness, an inhibitor must be cell-
permeable, as furin/PC cleavage of proMT1-MMP occurs primarily
within the Golgi/trans-Golgi network [35–37]. The search for furin/
PC inhibitors with the desired characteristics in terms of stability,
toxicity, and cell permeability is ongoing. These properties may be
found in a small-molecule inhibitor.
To search for small-molecule furin inhibitors, we performed a
high-throughput screening of several small-molecule libraries using
a cell-based assay [38]. As a result of this screen, we identified a
small-molecule inhibitor of furin, B3 (previously named CCG
8294 [38]), with a Ki and IC50 of 12 μM. Here, we show that this
cell-permeable, small-molecule inhibits furin processing of proMT1-
MMP, resulting in decreased MMP-2 activity and cell motility in
CHO cells expressing proMT1-MMP. Additionally, B3 inhibited
proMT1-MMP processing and invasiveness of human fibrosarcoma
cells (HT1080).
Materials and Methods
Reagents
decRVKR-CMK was purchased from Bachem (King of Prussia,
PA). decRVKR-CMK and B3 were dissolved in DMSO. B3 was
freshly dissolved in solution on the day of the experiment. BioCoat
Matrigel Invasion Chambers were purchased from BD Biosciences
(San Jose, CA). Concanavalin A (ConA) and polylysine were pur-
chased from Sigma (St. Louis, MO). Reagents used in zymography
were purchased from Invitrogen (Carlsbad, CA).
Compound Preparation (B3)
To prepare naphthofluorescein disodium salt (B3), a mixture of
1,6-dihydroxynaphthalene (9.6 g, 60 mmol) and phthalic anhydride
(4.44 g, 30 mmol) was heated at 200°C with vigorous stirring for
16 hours under a nitrogen atmosphere followed by cooling to room
temperature (RT). The resulting brown-black solid was treated with
an excess of acetic anhydride (50 ml) and refluxed for 3 hours. The
mixture was cooled to RT, treated with a mixture of crushed ice and
CH2Cl2 (200 ml), and stirred for 3 hours. The organic layer was
separated, washed with water (3 × 200 ml), and concentrated to give
12.35 g of black viscous oil. A 2.0-g portion was purified by repeated
(twice) silica-gel flash chromatography using a gradient of methanol
(1–3%) in CH2Cl2 to give 1.3 g (51.8%) as a tan solid. Next, a so-
lution of NaOH in methanol (0.25 M, 4 ml, 1.0 mmol) was added
dropwise with stirring (0.26 g, 0.5 mmol) under a nitrogen at-
mosphere. The intense dark blue suspension was stirred for an addi-
tional 30 minutes and concentrated. The residue was triturated with
methyl tert-butyl ether (MTBE) (2 × 10 ml) and concentrated. A
further portion of MTBE (20 ml) was added to the residue, the mix-
ture stirred for 20 minutes and filtered. The product was rinsed with
MTBE (2 × 5 ml) and dried (with protection from light) under high
vacuum at 60°C for 3 hours to give 0.23 g (98.7%) of B3 as blue-
black crystals: 1H nuclear magnetic resonance (DMSO-d6 + TMS,
400 MHz): σ 8.30 (d, J = 9.4 Hz, 2H), 8.12 (m, 1H), 7.54
(m, 2H), 7.15 (m, 1H), 6.95 (d, J = 9.2 Hz, 2H), 6.66 (dd, J =
9.3, 2.1 Hz, 2H), 6.49 (d, J = 9.0 Hz, 2H), 6.24 (d, J = 1.9 Hz,
2H); high-resolution mass spectrometry (electrospray ionization with
HCOOH added): predicted m/z for C28H17O5 [(M – ‵2Na
+ + 2H+) +
H]+ 433.1076, observed m/z 433.1073.
Cell Culture and Transfections
COS and HT1080 cells were maintained in DMEM containing
10% FBS, 1% l-glutamine, 100 μg/ml penicillin, and 100 μg/ml
streptomycin (P/S/G) (Gibco, Carlsbad, CA). Chinese hamster ovary
(CHO) cells were maintained in Ham’s F12 media with 10% FBS,
1 μMMEM nonessential amino acids (Gibco), and P/S/G. COS and
CHO cells were transfected with plasmid using Fugene 6 (Roche,
Indianapolis, IN) according to the manufacturer’s protocol. All cell
lines were incubated at 37°C with 5% CO2.
Drug Treatment Assays
COS cells were plated in 10 cm plates 24 hours before transfection
with plasmid-encoding proMMP-2. Twenty-four hours after trans-
fection, the media was replaced with OptiMEM (Gibco), and the
cells were allowed to incubate for 24 hours after which the condi-
tioned media was retrieved and centrifuged at 1000g for 10 minutes.
Supernatant was collected and placed on CHO cells transfected
with plasmid-encoding proMT1-MMP-HA ∼36 hours after transfec-
tion. The conditioned media from the CHO cells was collected after
8 hours of incubation. The media was centrifuged at 1000g for
5 minutes, and the supernatant was used for zymography or Western
blot analysis as indicated. For HT1080 experiments, 300,000 cells/
well were plated in six-well plates. After 24 hours of incubation, cells
were washed three times with media (no FBS) and were treated with
50 μg/ml ConA and the indicated concentration of drug. After an
overnight incubation, conditioned media was collected and concen-
trated using a filter device (Microcon YM-10; Millipore, Billerica,
MA). Cells were harvested for Western blot analysis as described.
Western Blot Analysis
Western blot analysis was performed as described [38]. Cells were
washed in PBS and lysed with a buffer containing 50 mM Tris (pH
7.4), 150 mM NaCl, 1% NP-40, supplemented with Complete Pro-
tease Inhibitor Cocktail (Roche). Cells were sonicated briefly, and the
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supernatant was collected after centrifugation. Protein concentration
was estimated using a detergent-compatible protein assay kit from
Bio-Rad (Hercules, CA). Media and lysates were separated by so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis, and protein
expression was detected by Western blot analysis using appropriate
primary antibody and HRP-conjugated secondary antibody followed
by chemiluminescent HRP substrate (Pierce, Rockford, IL). solMT1-
MMP expression was detected using a rabbit polyclonal antibody to
MT1-MMP (Chemicon, Temecula, CA). proMT1-MMP-HA ex-
pression was detected using a mouse monoclonal antibody to HA
(Covance, Princeton, NJ).
Zymography
The supernatant (10 μl) from cell assays was combined with run-
ning buffer without reducing agents and was applied to an agarose
gel containing 1% gelatin. After separation by electrophoresis, the gel
was placed in 1× renaturing buffer for 30 minutes and was then
washed with 1× developing buffer for 30 minutes after which the
buffer was replaced with fresh developing buffer and gel-incubated
for an additional 24 hours. The gels were stained with Coomassie
brilliant blue R250, and gelatinolytic activities were detected as clear
bands against a blue background.
Motility Assays
A 2-mg gelatin was combined with AlexaFluor 544 nm (Invitrogen),
900 μl of H2O, and 100 μl of 1 M NaHCO3. The components
were allowed to incubate for 1 hour and were then diluted 1:8 with
H2O. The labeled gelatin was then dialyzed against PBS at 4°C for
24 hours with two-to-three PBS changes. Slides were then prepared
by first coating with polylysine for 1 hour at RT. The labeled gelatin
was then diluted 1:20 in H2O, added to the slide, and allowed to
incubate for 2 hours at RT. The slide was fixed with glutaraldehyde
(1.5% in PBS) for 4 minutes at RT and was then washed three times
with PBS. The slide was blocked with NH4Cl (50 μM in PBS) for
10 minutes at RT and then washed three times with PBS. Ham’s F12
media was then added to the slide for incubation at 37°C. CHO cells
transfected with plasmid-encoding MT1-MMP-HA/green fluores-
cent protein (GFP) were trypsinized and washed 36 hours after trans-
fection and applied to slides containing OptiMEM media with
vehicle or drug. The cells and proteolytic tracks were visualized using
a fluorescence microscope (Eclipse TE2000-U; Nikon, Melville,
NY). Fluorescent images were acquired with Metamorph software
(Molecular Devices Corp, Sunnyvale, CA) using identical exposure
times. Proteolytic tracks were identified using Segmentation and
Thresholding tools, and track area (pixels) was measured using Region
Measurement tools in Metamorph software version 9 (Molecular De-
vices, Downingtown, PA). Tracks were measured from a minimum
of 10 random fields and were added together to provide total proteo-
lytic area. Proteolytic area was then expressed as percentage of con-
trol. This experiment was repeated eight times.
Toxicity Assays
CHO cells were plated in 96-well plates, treated with vehicle
(DMSO), 5, 10, 15, or 20 μM B3, and were allowed to incubate
for 16 hours. After incubation, a cell viability assay was performed
using WST-1 reagent (Roche) according to the manufacturer’s in-
structions. WST-1 reagent was added at the indicated time after
drug treatment and assayed. Absorbance was monitored at 460 nm
and background was monitored at 600 nm using a plate reader
(Fluorostar Optima; BMG Labtech, Chicago, IL). Final absorbance
units were computed by background subtraction.
Invasion Assays
Invasion assays were conducted using BioCoat Matrigel Invasion
Chambers (8-μm pore size) according to the manufacturer’s instruc-
tions. HT1080 cells (2.5 × 104 cells per well) were plated on inserts
in 24-well tissue culture plates using DMEM without FBS (and in-
dicated concentration of drug or vehicle) in upper chambers and
DMEM with 10% FBS as chemoattractant in lower chambers (and
indicated concentration of drug or vehicle). After 16 hours of incuba-
tion, noninvading cells were removed. Remaining cells were stained
using Diff-Quik stain set (Dade Behring, Newark, DE) according
to the manufacturer’s instructions. Membrane inserts were placed
on slides and visualized using a light microscope (Eclipse TE2000-U;
Nikon) (objective, ×10). Images were acquired with Metamorph soft-
ware (Molecular Devices Corp, Sunnyvale, CA). Images of 10 random
fields were taken, and cells were counted. Each cell treatment condition
was done in triplicate. Percent invasion was determined by dividing the
mean number of invading cells for the indicated treatment group by
the mean number of invading cells of control group.
Results
MT1-MMP–Dependent Activation of MMP-2 Is Inhibited By
Furin Inhibitor, B3
To evaluate the ability of the furin inhibitor, B3, to alter MT1-
MMP maturation, we used CHO cells expressing a secreted, soluble
form of proMT1-MMP (solMT1-MMP) [39] and performed Western
blot analysis using cell lysates. Expression of solMT1-MMP in these
cells resulted in the appearance of mature solMT1-MMP (∼57 kDa)
(Figure 1A). Coexpression of furin in solMT1-MMP–expressing cells
had no effect on solMT1-MMP maturation as solMT1-MMP
was completely processed by CHO cells. Treatment of CHO cells ex-
pressing solMT1-MMP with the well-characterized furin inhibitor,
decRVKR-CMK (20 μM), resulted in a decrease in processed solMT1-
MMP and appearance of unprocessed solMT1-MMP (∼60 kDa) and
served as a positive control. Similarly, treatment of cells with 15 μM
B3 resulted in a decrease in processed solMT1-MMP and the ap-
pearance of unprocessed solMT1-MMP. Coexpression of another
well-characterized furin inhibitor, α1-PDX [27], in solMT1-MMP–
expressing cells resulted in the appearance of unprocessed solMT1-
MMP in cell lysates and served as an additional positive control. We
also performed Western blot analysis using the conditioned media of
these same cells to confirm B3’s ability to inhibit solMT1-MMP mat-
uration. Expression of solMT1-MMP in these cells resulted in the ap-
pearance of mature solMT1-MMP (∼54 kDa) in the conditioned
media (Figure 1B). Treatment of cells expressing solMT1-MMP with
decRVKR-CMK (20 μM) or coexpression of α1-PDX resulted in
a decrease in mature solMT1-MMP and the appearance of unpro-
cessed solMT1-MMP (∼64 kDa) in the conditioned media. Similarly,
treatment of cells with 15 μM B3 resulted in a decrease in mature
solMT1-MMP and the appearance of unprocessed solMT1-MMP.
As previously mentioned, overexpression of furin in solMT1-MMP–
expressing cells had no further effect on MT1-MMP maturation.
Next, we investigated whether B3 would inhibit furin-mediated mat-
uration of membrane-bound proMT1-MMP. For this, we performed
Western blot analysis using cell lysates of CHO cells expressing an
HA-tagged proMT1-MMP (proMT1-MMP-HA) (Figure 1C ).
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CHO cells expressing empty vector (mock) did not express detectable
levels of MT1-MMP. In contrast, expression of proMT1-MMP-HA
plasmid in CHO cells (control) resulted in the appearance of both
the unprocessed (∼63 kDa) and processed forms (∼60 kDa) of
MT1-MMP. Treatment of these cells with decRVKR-CMK (20 μM)
resulted in a decrease in processed MT1-MMP and increase in the
pro-form of MT1-MMP and served as a positive control. Similarly,
treatment of cells with 15 μM B3 resulted in a decrease in processed
MT1-MMP and an increase in the proMT1-MMP compared to con-
trol. Expression of α1-PDX in proMT1-MMP-HA expressing cells also
resulted in a decrease in processed proMT1-MMP compared to control
cells. Furin cleaves MT1-MMP processes and activates its downstream
substrate, progelatinase (proMMP-2), to enzymatically active/mature
forms. To determine whether furin inhibition of MT1-MMP process-
ing would have a concomitant decrease in MMP-2 enzymatic activity,
we incubated proMT1-MMP-HA–expressing CHO cells with con-
ditioned media containing proMMP-2 in the absence or presence of
a furin inhibitor (Figure 1D). Zymographic analysis revealed that con-
ditioned media alone (media) had no MMP-2–related enzymatic ac-
tivity. When conditioned media containing proMMP-2 was added
to CHO cells expressing empty vector (mock), only the unprocessed
(∼66 kDa) and intermediate (∼62 kDa) forms of MMP-2 were de-
tected. In contrast, proMMP-2–containing conditioned media added
to CHO cells expressing proMT1-MMP-HA resulted in the detection
of unprocessed, intermediate, and mature forms (∼59 kDa) of MMP-2.
In the presence of B3 (15 μM) or decRVKR-CMK (20 μM), a sub-
stantial decrease in mature MMP-2 was detected. To determine the
dose dependence of furin inhibition on proMT1-MMP processing
and MMP-2 activation, we repeated the previously mentioned experi-
ment with various doses of B3. A dose-dependent decrease in proMT1-
MMP-HA maturation was observed on the analysis of cell lysates
(Figure 1E ). Concomitant zymographic analysis of MMP-2 activity
in the conditioned media also demonstrated a dose-dependant decrease
in MMP-2 activation (Figure 1F ). Some toxicity was observed with
cells treated with 20 μM B3.
Inhibition of Furin-Mediated MT1-MMP–dependent
Motility By B3
To functionally assess MT1-MMP–dependent activation of MMP-2,
we next performed a motility assay, monitoring the ability of CHO
cells expressing proMT1-MMP-HA/GFP to activate endogenous
MMP-2 (gelatinase). Active MMP-2 proteolyses its substrate, gelatin,
as the cell travels along a gelatin substratum. Wild-type CHO cells
do not degrade gelatin; however, CHO cells expressing MT-MMP
Figure 1. MT1-MMP–dependent activation of MMP-2 is inhibited by furin inhibitor, B3. (A) A representative Western blot of lysates or (B)
conditioned media of CHO cells expressing empty vector (−) or sol proMT1-MMP plasmid alone or in combination with α1-PDX or furin or
treated with decRVKR-CMK (20 μM) or B3 (15 μM) and probed with MT1-MMP antibody. An anti–BSA antibody was used as a loading
control for conditioned media. (C) A representative Western blot of lysates of CHO cells expressing empty vector (−) or proMT1-MMP-HA
plasmid alone or in combination with α1-PDX or treated with furin inhibitors decRVKR-CMK (20 μM) or B3 (15 μM) and probed with HA
antibody. (D) Zymographic analysis of conditioned media alone (media) or conditioned media containing proMMP-2 on CHO cells express-
ing empty vector (−) (mock) or CHO cells expressing proMT1-MMP-HA plasmid (control) and treated with either decRVKR-CMK (20 μM) or
B3 (15 μM). Asterisk (*) indicates the intermediate form of MMP-2. (E) A representative Western blot of lysates of CHO cells transfected
with empty vector (mock) or MT1-MMP-HA plasmid alone or in combination with indicated dose of B3 and probed with HA antibody. (F)
Zymogram analysis of conditioned media (media) or conditioned media containing proMMP-2 on CHO cells expressing empty vector (−)
(mock) or proMT1-MMP-HA plasmid and treated indicated concentration of B3. Asterisk (*) indicates the form of MMP-2.
366 B3 Inhibits Cancer Cell Motility and Invasiveness Coppola et al. Neoplasia Vol. 10, No. 4, 2008
proteolyse a gelatin substrate [23]. To test this, we transfected CHO
cells with an expression plasmid containing both proMT1-MMP-HA
and GFP, placed these cells on fluorescently labeled gelatin-plated
slides with or without furin inhibitory molecules, and monitored their
ability to degrade the gelatin substratum as they migrated across the
slide surface using fluorescence microscopy as described in Materials
and Methods. CHO cells expressing proMT1-MMP-HA/GFP (con-
trol) degraded fluorescently labeled gelatin, resulting in dark proteo-
lytic tracks (Figure 2A, subpanels A, B, and C ). proMT1-MMP-HA/
GFP–expressing CHO cells treated with the furin inhibitor,
decRVKR-CMK, had a significant decrease in motility compared to
control cells as indicated by the absence of proteolytic tracks (Fig-
ure 2A, subpanels D, E, and F ) and served as positive control.
proMT1-MMP-HA/GFP–expressing CHO cells treated with 15 μM
B3 had a significant decrease in motility compared to control cells, al-
though some slight motility remained (Figure 2A, subpanels G, H, and
I ). Ten randomly chosen fields were photographed from eight replicate
slides and proteolytic track area was measured as described in Materials
and Methods. Motility (total proteolytic area) was then computed and
expressed as a percentage of control (Figure 2B). proMT1-MMP-HA/
GFP–expressing CHO cells treated with decRVKR-CMK (positive
control) or B3 both had a significant reduction in motility (2–5%)
compared to control cells.
Inhibition of Furin-Mediated MT1-MMP Maturation and
MMP-2 Activation By B3 in HT1080 Cells
To investigate whether B3 would affect proMT1-MMP processing and
subsequent MMP-2 activity in a human cancer cell line, we performed
Figure 2. Inhibition of furin mediated MT1-MMP–dependent motility by B3. (A) Representative images of proteolysis of gelatin substrate by
CHO cells expressing proMT1-MMP and GFP (control, subpanels A, B, and C) and treated with decRVKR-CMK (20 μM) (subpanels D, E, and
F) or B3 (15 μM) (subpanels G, H, and I) as indicated and visualized by fluorescent microscopy. (B) Quantification of motility (%) for each of
the conditions shown in (A). For this, proteolytic track area (motility) was measured in 10 images of each treatment group as described in
Materials and Methods and was expressed as percentage of control. This experiment was replicated eight times (mean ± SD).
Neoplasia Vol. 10, No. 4, 2008 B3 Inhibits Cancer Cell Motility and Invasiveness Coppola et al. 367
the next series of experiments using the highly invasive human fibro-
sarcoma cell line, HT1080. HT1080 cells have increased levels of
processed MT1-MMP compared with other cell lines [40], which
is thought to contribute to their invasive ability. Additionally, treat-
ment of HT1080 cells with ConA enhances conversion of proMMP-2
into its active forms [25]. Treatment of HT1080 cells with ConA
(50 μg/ml) and increasing concentrations of B3 resulted in a decrease
in the mature MT1-MMP and a concomitant increase in proMT1-
MMP in a dose dependent manner, as observed by Western blot
analysis (Figure 3A). To determine whether this decrease in active
MT1-MMP would result in an increase in proMMP-2 in this cell
line, we performed zymography using the conditioned media of these
same cells. Zymogram analysis (Figure 3B) revealed conditioned
media from HT1080 cells treated with vehicle alone contained only
unprocessed MMP-2. Addition of ConA (50 μg/ml) to cells resulted
in processing of MMP-2 to intermediate and mature forms. Treat-
ment of these cells with both ConA and increasing concentrations
of B3 as previously mentioned resulted in a decrease in the mature
form and an increase in the intermediate and unprocessed forms of
MMP-2 in a dose-dependent manner with no alternations in MMP-9
activity (∼92 kDa, loading control).
B3 Decreases HT1080 Invasion
To functionally validate that inhibition of furin activity by B3 re-
sults in decreased invasive capacity, HT1080 cells were treated with
indicated doses of B3 or vehicle (control) (Figure 4). HT1080 con-
trol cells treated with vehicle alone freely invaded the membrane
(100% invasion). Cells treated with 5 μM B3 showed a slight de-
crease in membrane penetration. Cells treated with 10 μM B3 had
invasive ability reduced to ∼80% of control. 15 μM B3 was required
to inhibit invasive activity to ∼50% of control cells. Because doses
more than 20 μM resulted in some toxicity, higher doses of B3 were
not evaluated in this assay.
Discussion
Activation of MT1-MMP by furin directly contributes to the mo-
tility and invasiveness of the tumor cell [23,24]. Here, we have shown
that inhibition of furin activity prevents cleavage of proMT1-MMP
(Figures 1, B and D, and 3A) and subsequent activation of MMP-2
(Figures 1 C and 3B). Clearly, inhibition of furin activity did not com-
pletely prevent the activity of mature MMP-2 as shown by zymogra-
phy, but MMP-2 activity is often contingent on other factors [35,41].
Here, we show that B3 can inhibit furin cleavage of proMT1-MMP
and that this inhibition reduces the motility and invasiveness of cells.
Addition of B3 to CHO cells expressing proMT1-MMP resulted in an
almost complete inhibition of MMP-2–related cell motility (Figure 2,
A and B) and a 50% decrease in the invasiveness of the HT1080 cell
line (Figure 4). These functional experiments provide a direct means
to assess MT1-MMP–dependent MMP-2 activity and confirm furin
inhibition as a means to combat tumor cell motility and invasiveness
in vitro.
B3 was discovered by high-throughput screening with small-
molecule libraries using a cell-based assay and was confirmed as a
furin inhibitor in a series of secondary assays [38]. However, cellular
experiments indicate some toxicity associated with this molecule,
which becomes apparent when applied at concentrations of 20 μM
or more (data not shown). Preliminary experiments using small mol-
ecules with structural similarity to B3 have indicated that these mol-
ecules have inhibitory function toward furin, and other PC family
members, with IC50 values in the micromolar range. These molecules
also inhibit processing of the furin substrates pro–von Willebrand
Factor [42] and anthrax PA toxin [43], some with less toxicity than
that observed with B3 (unpublished data). In light of this, we believe
that B3 serves as an ideal candidate as a lead molecule for a new class
of cell-permeable furin inhibitors.
In addition to processing and activating proMT1-MMP, furin ac-
tivates a myriad of other proteins involved in cancer progression,
such as transforming growth factor β [5], insulin growth factor 1
and the insulin receptor [3], and vascular endothelial growth factor
Figure 3. Inhibition of furin-mediated MT1-MMP maturation and
MMP-2 activation by B3 in HT1080 cells. (A) A representative
Western blot of HT1080 lysates treated with vehicle or ConA
(50 μg/ml) and indicated dose of B3 and probed with MT1-MMP
antibody. (B) Zymographic analysis of conditioned media from
HT1080 cells treated with vehicle or ConA (50 ng/ml) and indicated
dose of B3.
Figure 4. B3 decreases HT1080 invasion. HT1080 cells were seeded
in transwell cell culture inserts coated with Matrigel and treated with
0, 5, 10, or 15 μM B3. Cells that had invaded through the membrane
were counted as described in Materials and Methods. Results are
expressed as percentage of control cells (mean ± SD).
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C/D [12,13]. Because of this, we believe that inhibition of furin may
be a more viable route to cancer therapy than the use of MT1-MMP
inhibitors. Recently, phase III clinical trials of MT1-MMP inhibitors
demonstrated no clinical efficacy [44]. Because furin/PCs act up-
stream of MT1-MMP and furin/PC activity is associated with acti-
vation of other substrates that contribute to cancer progression, furin
may be a more effective pharmaceutical target than MT1-MMP. Fu-
ture experiments will determine whether B3 can inhibit cleavage of
other furin substrates involved in tumorigenesis. Additionally, B3 in-
hibits other PC family members (unpublished results). Because other
PCs (PACE4 [21], PC5/6 [23], and PC7 [12,13]) are involved in
processing substrates necessary for tumor progression and invasion
[3], inhibition of multiple PCs may be necessary for complete sup-
pression of the cancer phenotype.
Furin activity is also necessary for the development of degenerative
diseases, such as arthritis, atherosclerosis, and Alzheimer’s disease
[1], and the propagation of viruses, such as avian influenza, human
immunodeficiency virus 1, Ebola, measles, cytomegalovirus, and
yellow fever [2,45]. Like MT1-MMP and other cancer-promoting
substrates, furin processing and activation of these substrates occur
primarily within the Golgi [35], which necessitate the use of a cell-
permeable inhibitor. Furin inhibition also thwarts the activation of
bacterial toxins, such as anthrax toxin, pseudomonas exotoxin A, Shiga
toxin, diphtheria toxin, and tetanus and botulism neurotoxins, which
are necessary for infectivity, and the virulence of these bacteria
[4,10,46–50]. Furin/PC inhibition may be a route to manage or cure
these debilitating and often fatal diseases. Future studies with this in-
hibitory molecule, or a structurally modified derivative, will enable ver-
ification of efficacy against cancer and other furin-mediated disease.
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